Trial Profile
Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Amifampridine (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions
- Acronyms MSK-003
- Sponsors Catalyst Pharmaceuticals
- 14 Apr 2023 Planned End Date changed from 30 Oct 2022 to 28 Apr 2023.
- 21 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Oct 2022.
- 21 Jul 2022 Planned primary completion date changed from 31 May 2022 to 30 Sep 2022.